Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Orv Hetil ; 164(32): 1271-1277, 2023 Aug 13.
Artigo em Húngaro | MEDLINE | ID: mdl-37573559

RESUMO

Our 69-year-old female patient was investigated for a 20 kg weight gain over 2 years. The patient's medical history included hypertension, hyperuricemia, bilateral cataract surgery and musculosceletal complaints. Diabetes mellitus was not found. Physical examination revealed abdominal obesity, proximal myopathy and atrophic, vulnerable skin. The "overnight", low-dose and long, low-dose dexamethasone suppression tests indicated autonomous cortisol overproduction (plasma cortisol level: 172.6 and 153.2 nmol/L, cut-off: 50 nmol/L). The suppressed ACTH (<1.11 pmol/L, normal value: 1.12-10.75 pmol/L) suggested ACTH-independent hypercortisolism. Abdominal CT described macronodular enlargement of both adrenals. The size of the largest nodule was 23 × 20 mm in the right, and 24 × 30 mm on the left side (with -33 ± 37 HU density values on native scans). The 131I-cholesterol adrenal scintigraphy and SPECT/CT showed almost equally intensive radiopharmacon uptake on both sides. Based on the clinical results, bilateral macronodular adrenal hyperplasia associated with ACTH-independent hypercortisolism was diagnosed. Genomic DNA was obtained from the peripheral blood leukocytes. Targeted sequencing of 25 genes potentially involved in adrenal tumorigenesis revealed a new disease-causing armadillo repeat-containing 5 (ARMC5) gene mutation (c.1724del28 bp, g.31,476,067-31,476,094). Because of the autosomal dominant inheritance of this genetic alteration, the patient's two children underwent genetic screening for the ARMC5 mutation. The same mutation was found in the younger child of our patient. To the best of our knowledge, this is the first published Hungarian case of ARMC5 mutation with bilateral macronodular adrenal hyperplasia and ACTH-independent Cushing's syndrome. The genetic alteration is present in two generations of the family of the index patient. Orv Hetil. 2023; 164(32): 1271-1277.


Assuntos
Hiperplasia Suprarrenal Congênita , Síndrome de Cushing , Feminino , Criança , Humanos , Idoso , Síndrome de Cushing/genética , Síndrome de Cushing/diagnóstico , Radioisótopos do Iodo , Hidrocortisona , Hiperplasia/genética , Proteínas Supressoras de Tumor/genética , Mutação , Hormônio Adrenocorticotrópico/genética , Proteínas do Domínio Armadillo/genética
2.
Cancer Biother Radiopharm ; 30(10): 433-8, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26683134

RESUMO

The present article describes the preparation of ß-emitter lutetium-177-labeled zirconia colloid and its preliminary physicochemical and biological evaluation of suitability for local radionuclide therapy. The new (177)Lu-labeled therapeutic radiopharmaceutical candidate was based on the synthesis mode of a previously described zirconia nanoparticle system. The size and shape of the developed radiopharmaceutical compound were observed through a scanning electron microscope and dynamic light scattering methods. The radiocolloid had a 1.7 µm mean diameter and showed high in vitro radiochemical and colloid size stability at room temperature and during the blood sera stability test. After the in vitro characterizations, the product was investigated in the course of the treatment of a spontaneously diseased dog veterinary patient's hock joint completed with single-photon emission computed tomography (SPECT) imaging follow-up measurements and a dual-isotope SPECT imaging tests with conventional (99m)Tc-methanediphosphonic acid bone scintigraphy. In the treated dog, no clinical side-effects or signs of histopathological changes of the joints were recorded during the treatment. SPECT follow-up studies clearly and conspicuously showed the localization of the (177)Lu-labeled colloid in the hock joint as well as detectable but negligible leakages of the radiocolloid in the nearest lymph node. On the basis of biological follow-up tests, the orthopedic team assumed that the (177)Lu-labeled zirconia colloid-based local radionuclide therapy resulted in a significant and long-term improvement in clinical signs of the patient without any remarkable side-effects.


Assuntos
Doenças do Cão/radioterapia , Lutécio/uso terapêutico , Osteoartrite/veterinária , Radioisótopos/uso terapêutico , Zircônio/uso terapêutico , Animais , Coloides , Cães , Lutécio/farmacocinética , Osteoartrite/radioterapia , Radioisótopos/farmacocinética , Membrana Sinovial/metabolismo , Articulações Tarsianas/diagnóstico por imagem , Tomografia Computadorizada de Emissão de Fóton Único , Zircônio/farmacocinética
3.
Magy Onkol ; 58(4): 239-44, 2014 Dec.
Artigo em Húngaro | MEDLINE | ID: mdl-25517441

RESUMO

Actual state of affairs and future perspectives of SPECT radiopharmaceuticals regarding local and international data were summarized. Beyond conventional gamma-emitting radioisotopes, localization studies with beta emitting therapeutic radiopharmaceuticals hold increasing importance. Extension of hybrid (SPECT/CT) equipments has modified conventional scintigraphic and SPECT methods as well but more important changes come into the world through novel ligands for specific diagnoses and therapy.


Assuntos
Neoplasias/diagnóstico por imagem , Compostos Radiofarmacêuticos , Tomografia Computadorizada de Emissão de Fóton Único/métodos , Tomografia Computadorizada por Raios X , Humanos , Radioisótopos
4.
Cancer Biother Radiopharm ; 29(8): 330-8, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25226213

RESUMO

The present article describes the preparation, characterization, and biological evaluation of Thulium-170 ((170)Tm) [T1/2 = 128.4 days; Eßmax = 968 keV; Eγ = 84 keV (3.26%)] labeled tin oxide microparticles for its possible use in radiation synovectomy (RSV) of medium-sized joints. (170)Tm was produced by irradiation of natural thulium oxide target. 170Tm-labeled microparticles were synthesized with high yield and radionuclidic purity (> 99%) along with excellent in vitro stability by following a simple process. Particle sizes and morphology of the radiolabeled particles were examined by light microscope, dynamic light scattering, and transmission electron microscope and found to be of stable spherical morphology within the range of 1.4-3.2 µm. The preparation was injected into the knee joints of healthy Beagle dogs intraarticularly for biological studies. Serial whole-body and regional images were taken by single-photon-emission computed tomography (SPECT) and SPECT-CT cameras up to 9 months postadministration, which showed very low leakage (< 8% of I.D.) of the instilled particles. The majority of leaked radiocolloid particles were found in inguinal lymph nodes during the 9 months of follow-up. All the animals tolerated the treatment well; the compound did not show any possible radiotoxicological effect. These preliminary studies showed that 170Tm-labeled microparticles could be a promising nontoxic and effective radiopharmaceutical for RSV applications or later local antitumor therapy.


Assuntos
Radioisótopos/administração & dosagem , Compostos Radiofarmacêuticos/administração & dosagem , Túlio/administração & dosagem , Animais , Cães , Masculino , Tamanho da Partícula , Radioisótopos/química , Compostos Radiofarmacêuticos/química , Membrana Sinovial/efeitos da radiação , Sinovite/radioterapia , Túlio/química , Distribuição Tecidual , Tomografia Computadorizada de Emissão de Fóton Único/métodos
5.
Int J Pharm ; 474(1-2): 91-4, 2014 Oct 20.
Artigo em Inglês | MEDLINE | ID: mdl-25093694

RESUMO

A new biocompatible, biodegradable, self-assembled chitosan-based nanoparticulate product was successfully synthesized and radiolabeled with technetium-99m, and studied as a potential new SPECT or SPECT/CT imaging agent for diagnosis of folate receptor overexpressing tumors. In the present study we examined the conditions of a preclinical application of this labeled nanosystem in early diagnosis of spontaneously diseased veterinary patient using a human SPECT/CT device. The results confirmed that the nanoparticles accumulated in tumor cells overexpressing folate receptors, contrast agent revealed higher uptake in the tumor for a long time. Preclinical trials verified that the new nanoparticles are able to detect folate-receptor-overexpressing tumors in spontaneously diseased animal models with enhanced contrast.


Assuntos
Quitosana/química , Receptores de Folato com Âncoras de GPI/análise , Receptores de Folato com Âncoras de GPI/metabolismo , Nanopartículas/química , Tomografia Computadorizada de Emissão de Fóton Único/métodos , Tomografia Computadorizada por Raios X/métodos , Animais , Materiais Biocompatíveis/síntese química , Materiais Biocompatíveis/química , Gatos , Quitosana/síntese química , Feminino , Neoplasias Bucais/diagnóstico , Neoplasias Bucais/metabolismo , Imagem Multimodal/métodos , Compostos Radiofarmacêuticos/síntese química , Compostos Radiofarmacêuticos/química
6.
Orv Hetil ; 152(10): 392-7, 2011 Mar 06.
Artigo em Húngaro | MEDLINE | ID: mdl-21354955

RESUMO

Beside conventional therapies for the treatment of neuroendocrine tumors, a new therapeutical approach, peptide receptor radionuclide therapy has been developed recently. There are two important features which make this therapy feasible: somatostatin receptors are strongly over-expressed in most neuroendocrine tumors resulting in a high tumor-to-background ratio and internalization of the somatostatin-receptor complex in neuroendocrine cells. Due to these features, neuroendocrine tumors can be treated with radiolabelled somatostatin analogues. For peptide receptor radionuclide therapy, somatostatin analogues are conjugated to a chelator that can bind a radionuclide. The most frequently used radionuclides for neuroendocrine tumor treatment are the ß-emitter Yttrium-90 (9°Y) and the ß+γ emitter Lutetium-177 (¹77Lu). Candidates for somatostatin receptor endoradiotherapy are patients with progressive, metastatic, somatostatin-receptor positive neuroendocrine tumors. Many patients have been successively treated with this approach: according to international results major remission can be achieved in 25% of the cases. Although this therapy is still unavailable in Hungary, Hungarian patients can be treated with somatostatin receptor endoradiotherapy with financial support from the National Health Fund in a co-operation with the University of Basel since 2005. During the past 5 years, 51 Hungarian patients have been treated with this therapy. This review briefly summarizes the theoretical background, indications, effectiveness and side effects of somatostatin receptor endoradiotherapy and the authors present the first data obtained from Hungarian patients.


Assuntos
Tumores Neuroendócrinos/radioterapia , Radioisótopos/uso terapêutico , Receptores de Somatostatina/efeitos da radiação , Adulto , Idoso , Feminino , Humanos , Hungria , Radioisótopos de Índio/uso terapêutico , Lutécio/uso terapêutico , Masculino , Pessoa de Meia-Idade , Tumores Neuroendócrinos/patologia , Radioterapia/efeitos adversos , Receptores de Somatostatina/metabolismo , Indução de Remissão , Radioisótopos de Ítrio/uso terapêutico
7.
Orv Hetil ; 152(10): 407-10, 2011 Mar 06.
Artigo em Húngaro | MEDLINE | ID: mdl-21354958

RESUMO

Somatostatin analogues represent a major treatment modality in the therapy of neuroendocrine tumors. Their efficacy is well documented in the inhibition of hormone secretion; however, novel data seem to underline their effectiveness in tumor regression, as well. In this report authors present a case of type 1 neuroendocrine tumors of the stomach associated with liver metastases. Somatostatin analogue treatment resulted in a complete regression of the primary tumor and the metastases within two years. This case draws attention on the importance of somatostatin analogue treatment not only in the control of hormonal symptoms but also in the inhibition of tumor growth.


Assuntos
Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/secundário , Tumores Neuroendócrinos/tratamento farmacológico , Octreotida/uso terapêutico , Somatostatina/análogos & derivados , Neoplasias Gástricas/patologia , Feminino , Humanos , Neoplasias Hepáticas/diagnóstico por imagem , Pessoa de Meia-Idade , Tumores Neuroendócrinos/diagnóstico por imagem , Tumores Neuroendócrinos/secundário , Cintilografia , Indução de Remissão , Somatostatina/uso terapêutico , Neoplasias Gástricas/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Resultado do Tratamento
8.
Orv Hetil ; 151(27): 1111-4, 2010 Jul 04.
Artigo em Húngaro | MEDLINE | ID: mdl-20558361

RESUMO

Verner and Morrison described a syndrome of watery diarrhea, hypokalemia, and achlorhydria (WDHA) in 1958. VIPomas producing high amounts of vasoactive intestinal peptide (VIP) commonly originate from the pancreas. Typical symptoms play a momentous role in the diagnosis of VIPoma. Diarrhea may persist for years before the diagnosis. Morbidity from untreated WDHA syndrome is associated with long-standing dehydration and with electrolyte and acid-base metabolism disorders, which may cause chronic renal failure. Assessment of specific marker (VIP) offers high sensitivity in establishing the diagnosis. Imaging modalities include endoscopic ultrasonography, computed tomography and magnetic resonance imaging, and particularly, scintigraphy with somatostatin analogues. Treatment options include resection of the tumor, chemotherapy or the reduction of symptoms with somatostatin analogues. Early diagnosis and management may affect survival of patients favorably. VIPoma cases may be associated with multiple endocrine neoplasia type 1.


Assuntos
Neoplasias Pancreáticas , Vipoma , Acloridria/etiologia , Idoso , Biomarcadores Tumorais/metabolismo , Diarreia/etiologia , Endossonografia , Feminino , Humanos , Hipopotassemia/etiologia , Imuno-Histoquímica , Imageamento por Ressonância Magnética , Neoplasia Endócrina Múltipla Tipo 1/complicações , Neoplasias Pancreáticas/complicações , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/tratamento farmacológico , Neoplasias Pancreáticas/cirurgia , Tomografia Computadorizada por Raios X , Peptídeo Intestinal Vasoativo/metabolismo , Vipoma/complicações , Vipoma/diagnóstico , Vipoma/tratamento farmacológico , Vipoma/cirurgia
11.
Magy Onkol ; 52(4): 351-5, 2008 Dec.
Artigo em Húngaro | MEDLINE | ID: mdl-19068462

RESUMO

Medulloblastoma is the most common malignant pediatric central nervous system tumor. Despite the adequate therapy the tumor often recurs. The primary medulloblastoma expresses somatostatin receptor-2 (SSTR-2), but so far we had no experience about the receptor status in recurrent tumors. The presence of SSTR-2 may have an important role in the early detection and treatment of recurrent medulloblastomas. Our aim was to examine the state of SSTR-2 expression in recurrent childhood medulloblastomas. We examined SSTR-2 expression by immunohistochemistry in primary and recurrent medulloblastoma samples of ten children treated with recurrent medulloblastoma at Semmelweis University, Departments of Pediatrics, between 1998 and 2004. All primary and recurrent tumors have been operated at the National Institute of Neurosurgery. We examined the intensity and the percentage of SSTR-2-positive tumor cells in the primary and recurrent tumor samples. All primary tumors were receptor-positive and SSTR-2 was also expressed in all recurrent medulloblastomas. In our samples the percentage of SSTR-2-positive tumor cells was 30-90%. As a positive in vivo control Octreoscan images were available in two cases. In these cases the results of immunohistochemistry and Octreoscan imaging seemed to correlate. As a conclusion, SSTR-2-positive recurrent tumors can be detected early by Octreoscan imaging, and the presence of SSTR-2 establishes the opportunity of applying somatostatin analogues (octreotide) in the treatment of recurrent childhood medulloblastoma.


Assuntos
Biomarcadores Tumorais/análise , Neoplasias Cerebelares/química , Meduloblastoma/química , Recidiva Local de Neoplasia/química , Receptores de Somatostatina/análise , Adolescente , Antineoplásicos Hormonais/uso terapêutico , Biomarcadores Tumorais/imunologia , Neoplasias Cerebelares/diagnóstico por imagem , Neoplasias Cerebelares/tratamento farmacológico , Neoplasias Cerebelares/patologia , Criança , Pré-Escolar , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Imuno-Histoquímica , Radioisótopos de Índio , Lactente , Masculino , Meduloblastoma/diagnóstico por imagem , Meduloblastoma/tratamento farmacológico , Meduloblastoma/secundário , Recidiva Local de Neoplasia/diagnóstico por imagem , Recidiva Local de Neoplasia/tratamento farmacológico , Recidiva Local de Neoplasia/patologia , Octreotida/uso terapêutico , Valor Preditivo dos Testes , Receptores de Somatostatina/imunologia , Somatostatina/análogos & derivados , Tomografia Computadorizada de Emissão de Fóton Único/métodos , Adulto Jovem
12.
J Pediatr Hematol Oncol ; 29(11): 774-5, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17984697

RESUMO

Although there has been considerable advancement in treatment techniques but still there are some illnesses that continue to exhibit a rather poor curability, such as thymoma. This report highlights the benefit of octreotide and prednisolone therapy in a 15-year-old girl, who was diagnosed with inoperable thymus carcinoma, with chemotherapy and radiotherapy being the last resort. The detection of type 2 somatostatin receptors on the surface of the tumor justified the introduction of treatment with somatostatin analog and prednisolone. Fortunately, after 6 months of this treatment, the tumor showed partial regression. However, 2 months later, somatostatin receptor negative metastases appeared; therefore, a switch over to imatinib became essential, because the tumor was CD-117 positive. Despite the therapy change, the patient's condition deteriorated owing to tumor progression.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Octreotida/uso terapêutico , Prednisolona/uso terapêutico , Timoma/tratamento farmacológico , Neoplasias do Timo/tratamento farmacológico , Adolescente , Feminino , Humanos , Timoma/diagnóstico , Neoplasias do Timo/diagnóstico , Resultado do Tratamento
13.
Magy Onkol ; 51(3): 229-34, 2007.
Artigo em Húngaro | MEDLINE | ID: mdl-17922063

RESUMO

Malignant solid tumors and leukemias are the second most common causes of death in childhood. The most frequent pediatric solid tumors are brain tumors. Brain tumors, especially medulloblastoma should be treated by surgery, irradiation and chemotherapy. However, chemotherapy has only moderate effect. Pediatric brain tumors, especially medulloblastomas, express somatostatin receptors. The aim of this study was the investigation of the expression of somatostatin receptors in pediatric brain tumors for diagnostic and therapeutic purpose. Fifty-six scintigraphic imagings (111In-DTPA-D-Phe1-octreotide) made in 45 children treated with brain tumor at the Unit of Oncology of the 2nd Department of Pediatrics, Semmelweis University. The diagnosis was medulloblastoma in 21 cases (46.7%). MRI scans have been performed parallel with the Octreoscan images. Octreoscan images were positive in 27 of 56 (48.2%) cases. The 27 positive Octreoscan images consisted of 16 medulloblastomas, 4 ependymomas, 4 astrocytomas and 3 glioblastomas. In 37 (66.1%) cases the results of Octreoscans were the same as those of the MRI scans. However, in 19 scans (33.9%) the outcome was different. Octreoscan imaging is not suitable for differential diagnosis in pediatric brain tumors, including medulloblastomas. Isotopes specifically binding to the somatostatin receptors (111In-DTPA-D-Phe1-octreotide) can be applied in medulloblastomas for diagnosis and follow-up treatment. In Octreoscan-positive tumors the Octreoscan images establish the opportunity to somatostatin analogue and/or specifically targeted radiation therapies.


Assuntos
Neoplasias Encefálicas/diagnóstico por imagem , Radioisótopos de Índio , Octreotida/análogos & derivados , Ácido Pentético/análogos & derivados , Receptores de Somatostatina/metabolismo , Adolescente , Astrocitoma/diagnóstico por imagem , Criança , Pré-Escolar , Ependimoma/diagnóstico por imagem , Feminino , Glioblastoma/diagnóstico por imagem , Humanos , Lactente , Recém-Nascido , Imageamento por Ressonância Magnética , Masculino , Meduloblastoma/diagnóstico por imagem , Cintilografia , Compostos Radiofarmacêuticos
14.
Orv Hetil ; 147(2): 51-9, 2006 Jan 15.
Artigo em Húngaro | MEDLINE | ID: mdl-16509213

RESUMO

INTRODUCTION: Primary aldosteronism is the most common form of mineralocorticoid hypertension. The disease has been described by Jerome W. Conn in 1955; since that time there has been a great progress in the knowledge concerning the prevalence, diagnostics and treatment of the disease. AIMS: The authors retrospectively analyzed the efficacy of diagnostic procedures and the outcome of treatment by the analysis of data of 187 patients with primary aldosteronism examined between 1958 and 2004 at the 2nd Department of Medicine of Semmelweis University. METHODS: The efficacy of different methods used for the diagnosis, the frequency of the different subtypes of primary aldosteronism, as well as the surgical outcomes in patients with surgically treated subtypes of primary aldosteronism were studied. RESULTS: Aldosterone-producing adenoma was detected in more than two thirds of patients (n = 135), whereas idiopathic hyperaldosteronism was found in 46 patients. Other subtypes of primary hyperaldosteronism occurred less frequently (unilateral primary adrenocortical hyperplasia in 5 patients and adrenocortical carcinoma in one patient). For the diagnosis of familial hyperaldosteronism type I, molecular biological studies of the aldosterone-synthase/11beta-hydroxylase gene chimera were carried out in 30 patients but none of them showed the presence of the chimeric gene. When comparing the clinical parameters of patients with aldosterone-producing adenoma and idiopathic hyperaldosteronism, no significant differences were found in the time period between the diagnosis of hypertension and the diagnosis of primary aldosteronism, or in the systolic and diastolic blood pressure values. The mean of the lowest documented serum potassium concentration was slightly lower in patients with aldosterone-producing adenoma (2.8 +/- 0.1 mmol/l) compared to those with idiopathic hyperaldosteronism (3.1 +/- 0.2 mmol/l), but the difference was not significant. Normokalemic primary hyperaldosteronism was found in 7 cases. The ratio of plasma aldosterone concentration (ng/dl) to plasma renin activity (ng/ml/h) was above 20 in all patients with aldosterone-producing adenoma and in all but 5 cases with idiopathic hyperaldosteronism. To confirm the diagnosis and to differentiate the subtypes of primary aldosteronism, the postural test combined with furosemide administration was performed in the majority of patients. When cases showing an elevation of plasma cortisol level during the test were excluded, this test differentiated patients with aldosterone-producing adenoma from those with idiopathic hyperaldosteronism with a sensitivity of 69% and a specificity of 92%. In cases of adrenocortical adenomas not or not clearly detectable by radiological imaging techniques, as well as in cases with bilateral adrenocortical adenomas, selective adrenal vein sampling was performed (n = 55). All but 4 patients with aldosterone-producing adenoma underwent adrenalectomy. Histology and postoperative hormone results confirmed the preoperative diagnosis in all operated patients. After surgery serum potassium concentration returned to normal in all patients showing low serum potassium levels before surgery. Also, the moderate to severe preoperative hypertension disappeared or improved after surgery. CONCLUSIONS: These observations are in contrast with the results of international studies which showed a high frequency of normokalemic primary aldosteronism and a more frequent occurrence of idiopathic hyperaldosteronism well treatable with aldosterone-antagonists. Therefore, it can be presumed that a significant number of primary aldosteronism cases that are not accompanied with severe hypokalemia remain undetected in Hungary.


Assuntos
Adenoma/cirurgia , Neoplasias do Córtex Suprarrenal/cirurgia , Aldosterona/metabolismo , Hiperaldosteronismo/diagnóstico , Hiperaldosteronismo/terapia , Antagonistas de Receptores de Mineralocorticoides/uso terapêutico , Adenoma/metabolismo , Neoplasias do Córtex Suprarrenal/metabolismo , Adrenalectomia , Adulto , Idoso , Citocromo P-450 CYP11B2/genética , Feminino , Humanos , Hungria/epidemiologia , Hiperaldosteronismo/sangue , Hiperaldosteronismo/complicações , Hiperaldosteronismo/epidemiologia , Hiperaldosteronismo/genética , Hiperpotassemia/etiologia , Hipertensão/etiologia , Masculino , Pessoa de Meia-Idade , Proteínas Mutantes Quiméricas/genética , Estudos Retrospectivos , Esteroide 11-beta-Hidroxilase/genética
15.
Orv Hetil ; 146(27): 1443-5, 2005 Jul 03.
Artigo em Húngaro | MEDLINE | ID: mdl-16089105

RESUMO

INTRODUCTION: The key to heal primary hyperparathyroidism is to find the hyper functioning parathyroid gland(s). Promoting this the perioperative isotope guided localization technique is worldwide used in the last years. AIM: Authors use this method since February, 2000. They present their experiences. METHODS: At 122 patients undergoing parathyroidectomy in last 5 years with diagnosis of primary hyperparathyroidism perioperative sestamibi scanning by gamma probe was taken to localize the adenoma. Tc-99m-sestamibi was administered 90-150 minutes before starting anesthesia. The distribution of activity was measured before operation percutaneously on the neck and during operation directly at explored parathyroid regions. Finally the removed specimens were ex vivo scanned. RESULTS: Because of the thyroid lobes also accumulate sestamibi the localizability of adenomas depended on direction of scanning. Important factor is the correct timing of isotope administration in order to achieve domination of parathyroid activity in time of measurement. Localization of adenomas by percutaneous measurement was correct in 36.1% of cases and by perioperative direct scanning in 66.4%. Furthermore, ex vivo scan of removed adenomas showed impressively high activity in all cases. CONCLUSIONS: In their experience sestamibi scanning lightens the operation only in a part of cases but probably it will be the most important method of localization if isotope selectively accumulating in parathyroid gland could be found. For the moment the greatest profit of this method is that the ex vivo measurement indicates the success of operation with great probability.


Assuntos
Adenoma/diagnóstico , Adenoma/cirurgia , Raios gama , Doenças das Paratireoides/diagnóstico , Doenças das Paratireoides/cirurgia , Paratireoidectomia , Adenoma/diagnóstico por imagem , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Feminino , Humanos , Período Intraoperatório , Masculino , Pessoa de Meia-Idade , Doenças das Paratireoides/diagnóstico por imagem , Cintilografia , Compostos Radiofarmacêuticos , Tecnécio Tc 99m Sestamibi
16.
Orv Hetil ; 143(21 Suppl 3): 1280-3, 2002 May 26.
Artigo em Húngaro | MEDLINE | ID: mdl-12077916

RESUMO

Searching for metastases of medullary thyroid cancer (MTC), FDG PET was applied. PET results were compared with those of conventional diagnostic imaging procedures. After primary treatment, 52 MTC patients with elevated serum tumor marker levels and/or general symptoms (diarrhoea/flush) underwent radiological (CT/MRI), 131-iodine labeled metaiodo-benzylguanidine (MIBG) whole-body scintigraphy and FDG PET investigations. At least one pathological lesion was detected in 49 patients by PET, 35 by CT, 32 by MRI and 3 by MIBG. FDG PET was far superior to the other methods in identifying metastases in the supradiaphragmatic lymphatic regions. In the follow-up of MTC patients, FDG PET was more sensitive in localizing tumorous LN involvement, especially in the cervical, supraclavicular and mediastinal lymphatic regions, compared to other imaging modalities.


Assuntos
Carcinoma Medular/diagnóstico por imagem , Carcinoma Medular/secundário , Neoplasias da Glândula Tireoide/diagnóstico por imagem , Neoplasias da Glândula Tireoide/patologia , Tomografia Computadorizada de Emissão , Adulto , Idoso , Neoplasias Ósseas/diagnóstico por imagem , Neoplasias Ósseas/patologia , Carcinoma Medular/terapia , Feminino , Fluordesoxiglucose F18 , Humanos , Radioisótopos do Iodo , Neoplasias Hepáticas/diagnóstico por imagem , Neoplasias Hepáticas/secundário , Neoplasias Pulmonares/diagnóstico por imagem , Neoplasias Pulmonares/secundário , Metástase Linfática/diagnóstico por imagem , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Compostos Radiofarmacêuticos , Estudos Retrospectivos , Neoplasias da Glândula Tireoide/terapia , Tomografia Computadorizada de Emissão/métodos , Tomografia Computadorizada por Raios X
17.
J Nucl Med ; 43(1): 66-71, 2002 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11801705

RESUMO

UNLABELLED: Postsurgically elevated or increasing serum calcitonin levels strongly suggest the presence of residual or recurrent medullary thyroid carcinoma (MTC). Several imaging modalities (sonography, MRI, CT, scintigraphy with different types of radiolabeled ligands, etc.) are routinely used in an attempt to localize tumorous tissue, but such efforts often fail. In the search for a more reliable method, 18F-FDG PET was applied to detect tumor tissue of residual or recurrent MTC. METHODS: Forty patients with a postoperatively elevated plasma calcitonin level were included. These patients underwent routine diagnostic imaging procedures (CT, MRI, and 131I-metaiodobenzylguanidine [MIBG] whole-body planar scintigraphy or SPECT) and 18F-FDG PET examinations. Two independent experts visually analyzed the images provided by each method to detect pathologic lesions. Lymph nodes of > or = 1 cm in short diameter that were detected by radiologic methods were considered to be pathologic. 18F-FDG accumulation with a sharp contour reported by both independent observers was similarly regarded as pathologic. RESULTS: PET detected 270 foci with a high tracer accumulation, whereas only 116 lesions were detected by MRI and 141 by CT. The numbers of such foci determined by PET, MRI, and CT were 98, 34, and 34, respectively, in the neck; 25, 5, and 6, respectively, in the supraclavicular regions; and 117, 35, and 39, respectively, in the mediastinum. 131I-MIBG scintigraphy findings were positive for only 3 patients. CONCLUSION: For MTC patients with a postoperatively elevated plasma tumor marker level, PET was more sensitive and superior in localizing tumorous lymph node involvement than were the other imaging modalities, especially in the cervical, supraclavicular, and mediastinal lymphatic regions.


Assuntos
Carcinoma Medular/diagnóstico por imagem , Carcinoma Medular/secundário , Fluordesoxiglucose F18 , Linfonodos/diagnóstico por imagem , Compostos Radiofarmacêuticos , Neoplasias da Glândula Tireoide/patologia , Tomografia Computadorizada de Emissão , Biomarcadores Tumorais/sangue , Calcitonina/sangue , Feminino , Humanos , Metástase Linfática , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Neoplasia Residual , Tomografia Computadorizada de Emissão de Fóton Único , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...